Niranjan Setty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Niranjan Setty has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ai Ling Tan
Pleural Medicine Unit, Institute for Respiratory Health, Nedlands, Perth, WA 6009, Australia
2 shared publications - Alice L. Crawford
Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia 2. Curtin Medical School, Curtin University, Perth, Australia
2 shared publications Brooke Kyle
Department of Respiratory Medicine Sir Charles Gairdner Hospital Perth West Australia Australia
2 shared publications- Yun Chor Gary Lee
University of Western Australia
2 shared publications Amjad Ali
Respiratory Medicine, Basildon and Thurrock University Hospitals, Mid and South Essex NHS Foundation Trust, Basildon, UK
1 shared publication- Arash Badiei
Department of Thoracic Medicine Royal Adelaide Hospital Adelaide Australia
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (5) , 68
The PASE Study: The Prevalence and Associations of Bendopnoea in Patients with Pneumothorax
Background: We recently established that bendopnoea (breathlessness upon bending forward) is common with pleural effusion; however, it has never been reported or investigated in patients with pneumothorax. This exploratory study investigated the prevalence and clinical relevance of bendopnoea in pneumothorax. Methods: Patients with pneumothorax of any aetiology or size were eligible. The presence of bendopnoea and time-to-bendopnoea was measured by bending the patient forward for 60 s and was assessed at baseline and post lung re-expansion. Results: Fifty patients (median age 48 years; 78% male) with primary spontaneous (48%), secondary spontaneous (24%) or iatrogenic (28%) pneumothorax were included. Pneumothorax size ranged from 7 to 99% of the hemithorax on chest radiographs. Most patients (74%) received conservative management. On a questionnaire, 48% (24/50) patients reported they experienced bendopnoea which “impacted daily life”. When bent forward, 32% (16/50) developed bendopnoea within 60 s. Patients with bendopnoea reported more breathlessness than those without bendopnoea on a 100 mm Visual Analogue Scale (VAS): median 46 [Q1–Q3 = 25–54] vs. 12 [3–32] mm, respectively, p = 0.0089; median difference −23 mm (95% CI −35 to −6). Those with bendopnoea showed a signal with worse chest pain on a 100 mm VAS for pain: median 28 [13–48] vs. 10 [2–42] mm, p = 0.0528; median difference −15 mm (95% CI −27 to 0). Shorter time-to-bendopnoea (i.e., worse bendopnoea) correlated with worse breathlessness (rs = −0.38, 95% CI −0.6 to −0.1; p = 0.0072) and more severe chest pain (rs = −0.29, 95% CI −0.5 to −0.007; p = 0.039). Conclusions: Bendopnoea can occur with pneumothorax, correlates with breathlessness and demonstrates a signal with worse chest pain.
- 22 September 2026
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 94 (5) , 68
Open AccessThe PASE Study: The Prevalence and Associations of Bendopnoea in Patients with Pneumothorax
Background: We recently established that bendopnoea (breathlessness upon bending forward) is common with pleural effusion; however, it has never been reported or investigated in patients with pneumothorax. This exploratory study investigated the prevalence and clinical relevance of bendopnoea in pneumothorax. Methods: Patients with pneumothorax of any aetiology or size were eligible. The presence of bendopnoea and time-to-bendopnoea was measured by bending the patient forward for 60 s and was assessed at baseline and post lung re-expansion. Results: Fifty patients (median age 48 years; 78% male) with primary spontaneous (48%), secondary spontaneous (24%) or iatrogenic (28%) pneumothorax were included. Pneumothorax size ranged from 7 to 99% of the hemithorax on chest radiographs. Most patients (74%) received conservative management. On a questionnaire, 48% (24/50) patients reported they experienced bendopnoea which “impacted daily life”. When bent forward, 32% (16/50) developed bendopnoea within 60 s. Patients with bendopnoea reported more breathlessness than those without bendopnoea on a 100 mm Visual Analogue Scale (VAS): median 46 [Q1–Q3 = 25–54] vs. 12 [3–32] mm, respectively, p = 0.0089; median difference −23 mm (95% CI −35 to −6). Those with bendopnoea showed a signal with worse chest pain on a 100 mm VAS for pain: median 28 [13–48] vs. 10 [2–42] mm, p = 0.0528; median difference −15 mm (95% CI −27 to 0). Shorter time-to-bendopnoea (i.e., worse bendopnoea) correlated with worse breathlessness (rs = −0.38, 95% CI −0.6 to −0.1; p = 0.0072) and more severe chest pain (rs = −0.29, 95% CI −0.5 to −0.007; p = 0.039). Conclusions: Bendopnoea can occur with pneumothorax, correlates with breathlessness and demonstrates a signal with worse chest pain.
- Open Access
- 2 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9)
Study Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time ( EVAPoRATe ) Pilot Multicentre Randomised Clinical Trial
Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital‐acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open‐labelled, pilot, multi‐centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow‐up. Secondary outcomes include total hospital length of stay, PAL‐related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full‐scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true
- 2 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (9)
Open AccessStudy Protocol of the Endobronchial VAlves for Pneumothorax to Reduce Admission Time ( EVAPoRATe ) Pilot Multicentre Randomised Clinical Trial
Background: Pneumothorax with persistent air leak (PAL) is a debilitating condition. Patients with PAL often require prolonged chest drainage, with associated complications, such as, hospital‐acquired infections, thromboembolism, and deconditioning. Endobronchial valves (EBVs) are an approved bronchoscopic treatment for PAL and may allow earlier chest tube removal and hospital discharge. Current evidence supporting the use of EBV is limited to case series and uncontrolled studies. EBVs are usually used as a last resort when other treatments failed. Whether early referral for EBV placement is feasible and can reduce hospital length of stay in patients with pneumothorax and PAL has not been tested in a randomised controlled trial (RCT). Methods: EVAPoRATe is a prospective, open‐labelled, pilot, multi‐centre RCT. Forty patients with pneumothorax of any cause and PAL who are unsuitable for or unwilling to undergo surgical management will be randomised 1:1 to the Early EBV Referral arm or the Standard Care arm. Patients in the Early EBV Referral arm will be assessed by an interventional clinician for EBV placement at the earliest feasible time from Day 5 of pneumothorax. Patients allocated to the Standard Care arm will receive conventional management by the attending team; EBV is allowed if clinically appropriate when air leak persists after 12 days. Participants will be followed for 6 months after discharge. Discussion: The primary outcome is the feasibility of the trial protocol, assessed by recruitment rate, adherence to the intervention arm, and retention at follow‐up. Secondary outcomes include total hospital length of stay, PAL‐related length of stay, interventions for PAL and EBV complications, time to air leak cessation, time to chest drain removal, pneumothorax recurrence, adverse events and serious adverse events, removal of EBVs, performance status, and mortality. This pilot feasibility study will assess whether a future full‐scale RCT of EBV for PAL is practical and will provide data to guide protocol refinement and sample size calculation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12625000360415; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=388086&isReview=true
- Open Access
- 8 December 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (12) , e70083
Oscillometry changes reflect clinically meaningful improvement after bronchial thermoplasty for uncontrolled asthma: A case report
Asthma is a highly prevalent but heterogenous condition. Uncontrolled disease is relatively common and may be due to ongoing inflammation and/or persisting bronchial hyper‐reactivity. Bronchial thermoplasty has been in use for many years but optimal case selection and post‐procedure assessment remain uncertain. We present a case of a gentleman in his 50s with lifelong asthma who experienced a persistent loss of control following influenza A in 2017. Despite multidisciplinary assessment and guideline‐based escalation of therapy, he had persisting symptoms. In the context of his atopy, he was trialled unsuccessfully on dupilumab. Bronchial thermoplasty (BT) was undertaken with good clinical benefit. Although his spirometry was little changed by BT, there was improvement in forced oscillometry technique (FOT) measurements. FOT may therefore be a useful addition to the assessment and monitoring of individuals considered for, or undergoing, BT.
- 8 December 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (12) , e70083
Open AccessOscillometry changes reflect clinically meaningful improvement after bronchial thermoplasty for uncontrolled asthma: A case report
Asthma is a highly prevalent but heterogenous condition. Uncontrolled disease is relatively common and may be due to ongoing inflammation and/or persisting bronchial hyper‐reactivity. Bronchial thermoplasty has been in use for many years but optimal case selection and post‐procedure assessment remain uncertain. We present a case of a gentleman in his 50s with lifelong asthma who experienced a persistent loss of control following influenza A in 2017. Despite multidisciplinary assessment and guideline‐based escalation of therapy, he had persisting symptoms. In the context of his atopy, he was trialled unsuccessfully on dupilumab. Bronchial thermoplasty (BT) was undertaken with good clinical benefit. Although his spirometry was little changed by BT, there was improvement in forced oscillometry technique (FOT) measurements. FOT may therefore be a useful addition to the assessment and monitoring of individuals considered for, or undergoing, BT.
- Open Access
- 24 January 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (1) , e01282
Untangling asthma, inducible laryngeal obstruction, and dysfunctional breathing in a competitive sportsperson
A young woman with historically mild asthma experienced worsening breathlessness and cough with competitive ice skating. Despite optimizing and escalating treatment for her eosinophilic asthma, and addressing known exacerbating factors, her symptoms remained uncontrolled and refractory to bronchodilators and oral corticosteroids. Objective testing suggested her presentation was out of keeping with asthma alone, and she was suspected to have comorbid dysfunctional breathing and/or inducible laryngeal obstruction. Evidence was required to confirm the diagnoses, assess each condition's contribution to her symptom burden, and guide therapy. As exercise was a predominant trigger, she proceeded to cardiopulmonary exercise test with continuous laryngoscopy during exercise (CPET‐CLE). Testing confirmed the presence of two forms of inducible laryngeal obstruction and evidence of hyperventilation predominant dysfunctional breathing. This case highlights the importance of identifying coexisting conditions in difficult‐to‐treat asthma, and the value of structured multidisciplinary assessment in referral centres for such individuals.
- 24 January 2024
- Published by Wiley in Respirology Case Reports
- Vol. 12 (1) , e01282
Open AccessUntangling asthma, inducible laryngeal obstruction, and dysfunctional breathing in a competitive sportsperson
A young woman with historically mild asthma experienced worsening breathlessness and cough with competitive ice skating. Despite optimizing and escalating treatment for her eosinophilic asthma, and addressing known exacerbating factors, her symptoms remained uncontrolled and refractory to bronchodilators and oral corticosteroids. Objective testing suggested her presentation was out of keeping with asthma alone, and she was suspected to have comorbid dysfunctional breathing and/or inducible laryngeal obstruction. Evidence was required to confirm the diagnoses, assess each condition's contribution to her symptom burden, and guide therapy. As exercise was a predominant trigger, she proceeded to cardiopulmonary exercise test with continuous laryngoscopy during exercise (CPET‐CLE). Testing confirmed the presence of two forms of inducible laryngeal obstruction and evidence of hyperventilation predominant dysfunctional breathing. This case highlights the importance of identifying coexisting conditions in difficult‐to‐treat asthma, and the value of structured multidisciplinary assessment in referral centres for such individuals.
- Open Access
- 2 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e239140
Rare cause of haemoptysis: bronchopulmonary sequestration
Bronchopulmonary sequestration is a rare congenital pulmonary abnormality of the lower airways, which includes an abnormal and non-functioning lung tissue not communicating with the tracheobronchial tree and having aberrant blood supply from systemic circulation with variable venous drainage. The incidence of sequestration is around 0.15%–6.4% of all congenital lung malformations.Common presenting features are cough and expectoration. Misdiagnosed cases may present with recurrent infections and haemoptysis. CT of the chest with contrast is the imaging modality of choice.This is a case report of a 32-year-old woman who presented with cough and haemoptysis. CT of the chest showed a multiloculated mass-like lesion in the left lower lobe with a feeding artery from coeliac plexus and venous drainage via the normal left pulmonary vein.Based on CT chest findings, diagnosis of intralobar pulmonary sequestration was made. The patient was reviewed by cardiothoracic surgeons and underwent surgical resection of the sequestrated lung. Common presenting features are cough and expectoration. Misdiagnosed cases may present with recurrent infections and haemoptysis. CT of the chest with contrast is the imaging modality of choice.
- 2 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e239140
Open AccessRare cause of haemoptysis: bronchopulmonary sequestration
Bronchopulmonary sequestration is a rare congenital pulmonary abnormality of the lower airways, which includes an abnormal and non-functioning lung tissue not communicating with the tracheobronchial tree and having aberrant blood supply from systemic circulation with variable venous drainage. The incidence of sequestration is around 0.15%–6.4% of all congenital lung malformations.Common presenting features are cough and expectoration. Misdiagnosed cases may present with recurrent infections and haemoptysis. CT of the chest with contrast is the imaging modality of choice.This is a case report of a 32-year-old woman who presented with cough and haemoptysis. CT of the chest showed a multiloculated mass-like lesion in the left lower lobe with a feeding artery from coeliac plexus and venous drainage via the normal left pulmonary vein.Based on CT chest findings, diagnosis of intralobar pulmonary sequestration was made. The patient was reviewed by cardiothoracic surgeons and underwent surgical resection of the sequestrated lung. Common presenting features are cough and expectoration. Misdiagnosed cases may present with recurrent infections and haemoptysis. CT of the chest with contrast is the imaging modality of choice.